Guggenheim Cuts Price Target for Valneva SE
Guggenheim has lowered its price target for Valneva SE (VALN) from $13 to $11. This adjustment reflects a revised financial outlook for the European biotechnology company.
Results for "Valneva SE"
3 stories found
Pfizer-Valneva Lyme Vaccine Shows Strong Efficacy But Faces Approval Hurdles
Pfizer and Valneva reported strong efficacy data from their Lyme disease vaccine trial, though the candidate reportedly missed a specific mark, potentially complicating its path to regulatory approval from the FDA.
Valneva Sees Lower 2026 Sales as Third-Party Revenue Winds Down
Valneva anticipates lower sales in 2026 due to the reduction of third-party revenue.